{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:33:36Z","timestamp":1761860016211,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Science & Technology Major Project of China","award":["2017ZX09301012-006"],"award-info":[{"award-number":["2017ZX09301012-006"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81603380"],"award-info":[{"award-number":["81603380"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Strategic Priority Research Program of the Chinese Academy of Sciences","award":["XDA12050306"],"award-info":[{"award-number":["XDA12050306"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Analysis"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jpha.2018.09.001","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T06:14:26Z","timestamp":1536300866000},"page":"25-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Assay development for determination of DZ2002, a new reversible SAHH inhibitor, and its acid metabolite DZA in blood and application to rat pharmacokinetic study"],"prefix":"10.1016","volume":"9","author":[{"given":"Weiwei","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifei","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olajide E.","family":"Olaleye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danghui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpha.2018.09.001_bib1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1359-6446(05)03383-0","article-title":"Mammalian carboxylesterases: from drug targets to protein therapeutics","volume":"10","author":"Redinbo","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jpha.2018.09.001_bib2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1124\/jpet.104.080416","article-title":"Inhibition of S-adenosyl-L-homocysteine hydrolase induces immunosuppression","volume":"313","author":"Wu","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jpha.2018.09.001_bib3","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1124\/jpet.105.093369","article-title":"S-adenosyl-L-homocysteine hydrolase inactivation curtails ovalbumin-induced immune responses","volume":"316","author":"Fu","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jpha.2018.09.001_bib4","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1124\/jpet.106.107185","article-title":"A reversible S-adenosyl-L-homocysteine hydrolase inhibitor ameliorates experimental autoimmune encephalomyelitis by inhibiting T cell activation","volume":"319","author":"Fu","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jpha.2018.09.001_bib5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/aps.2013.167","article-title":"Therapeutic effects of DZ2002, a reversible SAHH inhibitor, on lupus-prone NZBxNZW F1 mice via interference with TLR-mediated APC response","volume":"35","author":"He","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jpha.2018.09.001_bib6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.phrs.2017.11.012","article-title":"Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF-\u03b1\/IFN-\u03b3-induced inflammatory response in keratinocytes and T cell-derived IL-17","volume":"129","author":"Lin","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jpha.2018.09.001_bib7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2174\/187231209788654081","article-title":"Esterase activities in the blood, liver and intestine of several preclinical species and humans","volume":"3","author":"Berry","year":"2009","journal-title":"Drug Metab. Lett."},{"key":"10.1016\/j.jpha.2018.09.001_bib8","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1002\/jps.23258","article-title":"Species difference of esterase expression and hydrolase activity in plasma","volume":"101","author":"Bahar","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpha.2018.09.001_bib9","doi-asserted-by":"crossref","first-page":"6646","DOI":"10.1016\/j.chroma.2011.07.042","article-title":"Accurate determination of the anticancer prodrug simmitecan and its active metabolite chimmitecan in various plasma samples based on immediate deactivation of blood carboxylesterases","volume":"1218","author":"Hu","year":"2011","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpha.2018.09.001_bib10","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpha.2018.09.001_bib11","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpha.2018.09.001_bib12","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1023\/A:1026451721686","article-title":"Confidence interval criteria for assessment of dose proportionality","volume":"17","author":"Smith","year":"2000","journal-title":"Pharm. Res."}],"container-title":["Journal of Pharmaceutical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095177918302867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095177918302867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:30:01Z","timestamp":1761859801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095177918302867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S2095177918302867"],"URL":"https:\/\/doi.org\/10.1016\/j.jpha.2018.09.001","relation":{},"ISSN":["2095-1779"],"issn-type":[{"type":"print","value":"2095-1779"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assay development for determination of DZ2002, a new reversible SAHH inhibitor, and its acid metabolite DZA in blood and application to rat pharmacokinetic study","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpha.2018.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Xi'an Jiaotong University. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}